Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis

Fig. 2

CR rate in IDH-mutant AML patients treated with IDH inhibitors. A Newly diagnosed AML patients treated with IDH inhibitors; B Newly diagnosed AML patients treated with IDH inhibitors in combination; C Newly diagnosed AML patients treated with IDH inhibitors alone; D Relapsed or refractory AML patients treated with IDH inhibitors; E Relapsed or refractory AML patients treated with IDH inhibitors alone. CR complete remission, AML acute myeloid leukemia, IDH isocitrate dehydrogenase genes, 95% CI 95% confidence interval

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us